Study #2025-0074
A phase 1b open-label study to evaluate the safety and tolerability of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia
MD Anderson Study Status
Enrolling
Treatment Agent
Eganelisib, Eganelisib in combination with cytarabine
Description
This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination. * Part 2: Dose Optimization
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
AML, Adult, MDS
Study phase:
Phase I
Physician name:
Tapan Kadia
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?